tiprankstipranks
Merck & Company (MRK)
NYSE:MRK
US Market
MRK
Merck & Company
RESEARCH TOOLSreports
Want to see MRK full AI Analyst Report?

Merck & Company (MRK) Stock Forecast & Price Target

14,788 Followers
See the Price Targets and Ratings of:

MRK Analyst Ratings

Moderate Buy
21Ratings
Moderate Buy
14 Buy
7 Hold
0 Sell
Based on 21 analysts giving stock ratings to
Merck
& Company
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MRK Stock 12 Month Forecast

Average Price Target

$134.55
▲(13.00% Upside)
Based on 21 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is $134.55 with a high forecast of $179.00 and a low forecast of $100.00. The average price target represents a 13.00% change from the last price of $119.07.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"72":"$72","99":"$99","126":"$126","153":"$153","180":"$180"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":179,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$179.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":134.55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$134.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[72,99,126,153,180],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,120.84,125.31384615384616,129.7876923076923,134.26153846153846,138.73538461538462,143.20923076923077,147.68307692307692,152.15692307692308,156.63076923076923,161.10461538461539,165.57846153846154,170.0523076923077,174.52615384615385,{"y":179,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,120.84,121.89461538461539,122.94923076923078,124.00384615384615,125.05846153846154,126.11307692307693,127.16769230769232,128.2223076923077,129.27692307692308,130.33153846153846,131.38615384615386,132.44076923076923,133.49538461538464,{"y":134.55,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,120.84,119.23692307692308,117.63384615384615,116.03076923076924,114.42769230769231,112.82461538461538,111.22153846153846,109.61846153846155,108.01538461538462,106.41230769230769,104.80923076923077,103.20615384615385,101.60307692307693,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":84.066,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.341,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.577,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.732,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.276,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.984,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.709,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.624,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.224,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.486,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.536,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.517,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.84,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$179.00Average Price Target$134.55Lowest Price Target$100.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BMO Capital Analyst forecast on MRK
Evan Seigerman
BMO Capital
BMO Capital
$112.89→$135
Buy
13.38%
Upside
Assigned
04/23/26
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (NASDAQ: ISRG), Quest Diagnostics (NYSE: DGX) and Merck & Company (NYSE: MRK)
Wells Fargo Analyst forecast on MRK
Mohit Bansal
Wells Fargo
Wells Fargo
$150
Buy
25.98%
Upside
Reiterated
04/22/26
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Allogene Therapeutics (ALLO)
Goldman Sachs Analyst forecast on MRK
Asad Haider
Goldman Sachs
Goldman Sachs
$133
Buy
11.70%
Upside
Reiterated
04/22/26
Analysts' Top Healthcare Picks: Merck & Company (MRK), Regeneron (REGN)
Bernstein Analyst forecast on MRK
Courtney Breen
Bernstein
Bernstein
$100
Hold
-16.02%
Downside
Reiterated
04/21/26
Bernstein Keeps Their Hold Rating on Merck & Company (MRK)
Barclays Analyst forecast on MRK
Emily Field
Barclays
Barclays
$140
Buy
17.58%
Upside
Reiterated
04/21/26
Barclays Remains a Buy on Merck & Company (MRK)
Rothschild & Co Redburn Analyst forecast on MRK
Natalya Davies
Rothschild & Co Redburn
Rothschild & Co Redburn
$179
Buy
50.33%
Upside
Reiterated
04/17/26
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Savara (SVRA)
Morgan Stanley Analyst forecast on MRK
Terence Flynn
Morgan Stanley
Morgan Stanley
$101→$109
Hold
-8.46%
Downside
Reiterated
04/15/26
Morgan Stanley Sticks to Its Hold Rating for Merck & Company (MRK)
UBS Analyst forecast on MRK
Michael Yee
UBS
UBS
$130→$145
Buy
21.78%
Upside
Assigned
04/13/26
Merck price target raised to $145 from $130 at UBSMerck price target raised to $145 from $130 at UBS
Jefferies Analyst forecast on MRK
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$138
Buy
15.90%
Upside
Reiterated
04/09/26
Merck & Company (MRK) Gets a Buy from Jefferies
Guggenheim Analyst forecast on MRK
Vamil Divan
Guggenheim
Guggenheim
$140
Buy
17.58%
Upside
Reiterated
04/08/26
Analysts' Top Healthcare Picks: Oruka Therapeutics (ORKA), Merck & Company (MRK)
RBC Capital Analyst forecast on MRK
Trung Huynh
RBC Capital
RBC Capital
$142
Buy
19.26%
Upside
Reiterated
04/07/26
Analysts Are Bullish on These Healthcare Stocks: Inventiva (IVA), Stereotaxis (STXS)
J.P. Morgan Analyst forecast on MRK
Chris Schott
J.P. Morgan
J.P. Morgan
$125→$135
Buy
13.38%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and Agios Pharma (NASDAQ: AGIO)
Erste Group Analyst forecast on MRK
Hans Engel
Erste Group
Erste Group
―
Hold
―
Reiterated
04/02/26
Erste Group Sticks to Its Hold Rating for Merck & Company (MRK)
TD Cowen Analyst forecast on MRK
Steve Scala
TD Cowen
TD Cowen
$120→$137
Hold
15.06%
Upside
Reiterated
03/30/26
Analysts Conflicted on These Healthcare Names: Connect Biopharma Holdings (NASDAQ: CNTB), Neumora Therapeutics, Inc. (NASDAQ: NMRA) and Merck & Company (NYSE: MRK)
Scotiabank Analyst forecast on MRK
Louise Chen
Scotiabank
Scotiabank
$136
Buy
14.22%
Upside
Reiterated
03/30/26
Scotiabank Reaffirms Their Buy Rating on Merck & Company (MRK)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BMO Capital Analyst forecast on MRK
Evan Seigerman
BMO Capital
BMO Capital
$112.89→$135
Buy
13.38%
Upside
Assigned
04/23/26
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (NASDAQ: ISRG), Quest Diagnostics (NYSE: DGX) and Merck & Company (NYSE: MRK)
Wells Fargo Analyst forecast on MRK
Mohit Bansal
Wells Fargo
Wells Fargo
$150
Buy
25.98%
Upside
Reiterated
04/22/26
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Allogene Therapeutics (ALLO)
Goldman Sachs Analyst forecast on MRK
Asad Haider
Goldman Sachs
Goldman Sachs
$133
Buy
11.70%
Upside
Reiterated
04/22/26
Analysts' Top Healthcare Picks: Merck & Company (MRK), Regeneron (REGN)
Bernstein Analyst forecast on MRK
Courtney Breen
Bernstein
Bernstein
$100
Hold
-16.02%
Downside
Reiterated
04/21/26
Bernstein Keeps Their Hold Rating on Merck & Company (MRK)
Barclays Analyst forecast on MRK
Emily Field
Barclays
Barclays
$140
Buy
17.58%
Upside
Reiterated
04/21/26
Barclays Remains a Buy on Merck & Company (MRK)
Rothschild & Co Redburn Analyst forecast on MRK
Natalya Davies
Rothschild & Co Redburn
Rothschild & Co Redburn
$179
Buy
50.33%
Upside
Reiterated
04/17/26
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Savara (SVRA)
Morgan Stanley Analyst forecast on MRK
Terence Flynn
Morgan Stanley
Morgan Stanley
$101→$109
Hold
-8.46%
Downside
Reiterated
04/15/26
Morgan Stanley Sticks to Its Hold Rating for Merck & Company (MRK)
UBS Analyst forecast on MRK
Michael Yee
UBS
UBS
$130→$145
Buy
21.78%
Upside
Assigned
04/13/26
Merck price target raised to $145 from $130 at UBSMerck price target raised to $145 from $130 at UBS
Jefferies Analyst forecast on MRK
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$138
Buy
15.90%
Upside
Reiterated
04/09/26
Merck & Company (MRK) Gets a Buy from Jefferies
Guggenheim Analyst forecast on MRK
Vamil Divan
Guggenheim
Guggenheim
$140
Buy
17.58%
Upside
Reiterated
04/08/26
Analysts' Top Healthcare Picks: Oruka Therapeutics (ORKA), Merck & Company (MRK)
RBC Capital Analyst forecast on MRK
Trung Huynh
RBC Capital
RBC Capital
$142
Buy
19.26%
Upside
Reiterated
04/07/26
Analysts Are Bullish on These Healthcare Stocks: Inventiva (IVA), Stereotaxis (STXS)
J.P. Morgan Analyst forecast on MRK
Chris Schott
J.P. Morgan
J.P. Morgan
$125→$135
Buy
13.38%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and Agios Pharma (NASDAQ: AGIO)
Erste Group Analyst forecast on MRK
Hans Engel
Erste Group
Erste Group
―
Hold
―
Reiterated
04/02/26
Erste Group Sticks to Its Hold Rating for Merck & Company (MRK)
TD Cowen Analyst forecast on MRK
Steve Scala
TD Cowen
TD Cowen
$120→$137
Hold
15.06%
Upside
Reiterated
03/30/26
Analysts Conflicted on These Healthcare Names: Connect Biopharma Holdings (NASDAQ: CNTB), Neumora Therapeutics, Inc. (NASDAQ: NMRA) and Merck & Company (NYSE: MRK)
Scotiabank Analyst forecast on MRK
Louise Chen
Scotiabank
Scotiabank
$136
Buy
14.22%
Upside
Reiterated
03/30/26
Scotiabank Reaffirms Their Buy Rating on Merck & Company (MRK)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merck & Company

3 Months
xxx
Success Rate
18/28 ratings generated profit
64%
Average Return
+4.81%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +4.81% per trade.
1 Year
Daina GrayboschLeerink Partners
Success Rate
36/52 ratings generated profit
69%
Average Return
+12.79%
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +12.79% per trade.
2 Years
xxx
Success Rate
18/21 ratings generated profit
86%
Average Return
+21.06%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +21.06% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRK Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
0
1
Buy
20
27
32
40
41
Hold
17
19
18
22
19
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
37
46
50
62
61
In the current month, MRK has received 42 Buy Ratings, 19 Hold Ratings, and 0 Sell Ratings. MRK average Analyst price target in the past 3 months is 134.55.
Each month's total comprises the sum of three months' worth of ratings.

MRK Financial Forecast

MRK Earnings Forecast

Next quarter’s earnings estimate for MRK is -$1.47 with a range of -$1.81 to -$0.83. The previous quarter’s EPS was $2.04. MRK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MRK has Performed in-line its overall industry.
Next quarter’s earnings estimate for MRK is -$1.47 with a range of -$1.81 to -$0.83. The previous quarter’s EPS was $2.04. MRK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MRK has Performed in-line its overall industry.

MRK Sales Forecast

Next quarter’s sales forecast for MRK is $15.85B with a range of $15.23B to $16.32B. The previous quarter’s sales results were $16.32B. MRK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MRK has Performed in-line its overall industry.
Next quarter’s sales forecast for MRK is $15.85B with a range of $15.23B to $16.32B. The previous quarter’s sales results were $16.32B. MRK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MRK has Performed in-line its overall industry.

MRK Stock Forecast FAQ

What is MRK’s average 12-month price target, according to analysts?
Based on analyst ratings, Merck & Company’s 12-month average price target is 134.55.
    What is MRK’s upside potential, based on the analysts’ average price target?
    Merck & Company has 13.00% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MRK a Buy, Sell or Hold?
          Merck & Company has a consensus rating of Moderate Buy which is based on 14 buy ratings, 7 hold ratings and 0 sell ratings.
            What is Merck & Company’s price target?
            The average price target for Merck & Company is 134.55. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $179.00 ,the lowest forecast is $100.00. The average price target represents 13.00% Increase from the current price of $119.07.
              What do analysts say about Merck & Company?
              Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.
                How can I buy shares of MRK?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.